SEC Form 4 · accession 0001209191-15-052576
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francois Lebel
Officer — Executive Vice President R&D
Period of report
Jun 9, 2015
Accepted (ET)
Jun 11, 2015 · 9:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 9, 2015 | M | 50,000 | $4.34 | A | 50,000 | D | |
| Common Stock | Jun 9, 2015 | S | 50,000 | $10.12 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.34 | Jun 9, 2015 | M | 50,000 | D | — | Dec 30, 2023 | Common Stock | 50,000 | 100,000 | D |
Explanation of responses
- F1The option is vested with respect to 50,000 shares; the option vests with respect to the remaining 100,000 shares on 12/31/2015 and 12/31/2016.